T cell receptors
US11505590B2 · kind B2 · utility
3Cited by
0References
45Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Apr 7, 2017 |
| Grant date | Nov 22, 2022 |
| Priority date | — |
| Expiry date | Mar 12, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/035
- WIPO fieldBiotechnology
- WIPO sectorChemistry
Abstract
The present invention relates to T cell receptors (TCRs) that bind the HLA-A*02 restricted peptide GVYDGREHTV (SEQ ID NO: 1) derived from the germline cancer antigen MAGE A4. Said TCRs may comprise non-natural mutations within the alpha and/or beta variable domains relative to a native MAGE A4 TCR. The TCRs of the invention are particularly suitable for use as novel immunotherapeutic reagents for the treatment of malignant disease.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.